Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

NSCLC and HER2 Between Lights and Shadows

NSCLC and HER2 Between Lights and Shadows STATE OF THE ART: CONCISE REVIEw NSCLC and HER2 Between Lights and Shadows Giuseppina Rosaria Rita Ricciardi, MD, Alessandro Russo, MD, Tindara Franchina, MD, Giuseppa Ferraro, MD, Mariangela Zanghì, MD, Antonio Picone, MD, Antonino Scimone, MD, and Vincenzo Adamo, MD the rediscover of hastily thrown out drugs, such as neratinib. The aim Abstract: The therapeutic landscape of non–small-cell lung cancer of this article is to provide an overview of the role of HER2 dysregu- (NSCLC) has dramatically changed in the last few years with the lation in NSCLCs, trying to throw a light not only on the strengths introduction of molecularly targeted agents, leading to unprecedented but also the weaknesses of the studies conducted so far. It is a long results in lung tumors with a paradigmatic shift from a “one size fits way to the clinical implementation of these biomarkers and probably all” approach to an histologic and molecular-based approach. The the increasing use of next generation sequencing techniques, the cre- discovery of epidermal growth factor receptor (EGFR) mutations ation of large multi-institutional molecular testing platforms and the in NSCLC in 2004 and the marked response to the EGFR tyrosine design of rationally based trials can get closer personalized medicine http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

NSCLC and HER2 Between Lights and Shadows

Journal of Thoracic Oncology , Volume 9 (12) – Dec 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/nsclc-and-her2-between-lights-and-shadows-i0404ZMH2a

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

STATE OF THE ART: CONCISE REVIEw NSCLC and HER2 Between Lights and Shadows Giuseppina Rosaria Rita Ricciardi, MD, Alessandro Russo, MD, Tindara Franchina, MD, Giuseppa Ferraro, MD, Mariangela Zanghì, MD, Antonio Picone, MD, Antonino Scimone, MD, and Vincenzo Adamo, MD the rediscover of hastily thrown out drugs, such as neratinib. The aim Abstract: The therapeutic landscape of non–small-cell lung cancer of this article is to provide an overview of the role of HER2 dysregu- (NSCLC) has dramatically changed in the last few years with the lation in NSCLCs, trying to throw a light not only on the strengths introduction of molecularly targeted agents, leading to unprecedented but also the weaknesses of the studies conducted so far. It is a long results in lung tumors with a paradigmatic shift from a “one size fits way to the clinical implementation of these biomarkers and probably all” approach to an histologic and molecular-based approach. The the increasing use of next generation sequencing techniques, the cre- discovery of epidermal growth factor receptor (EGFR) mutations ation of large multi-institutional molecular testing platforms and the in NSCLC in 2004 and the marked response to the EGFR tyrosine design of rationally based trials can get closer personalized medicine

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Dec 1, 2014

There are no references for this article.